Short course immune induction therapy

Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Mittwoch, Oktober 4, 2023
Abstract, Cleveland Clinic, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Vaccine, Pharmacovigilance, Short course immune induction therapy

The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • The presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Retrieved on: 
Dienstag, August 22, 2023
AFL, Disability, Biotechnology, Clinical trial, Research, Biomarker, Multiple sclerosis, MS, EDSS, RMS, PMS, Patient, Safety, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, August 17, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the completion of enrollment of its phase 2 CALLIPER trial of lead asset, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).

Key Points: 
  • NEW YORK, August 17, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the completion of enrollment of its phase 2 CALLIPER trial of lead asset, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).
  • In total, 467 patients with primary PMS, or active or non-active secondary PMS have been randomized to either 45mg of vidofludimus calcium or placebo.
  • The trial, running concurrently and as a complement to the company’s twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS), is focused on progressive forms of multiple sclerosis (MS) and is designed to corroborate vidofludimus calcium’s neuroprotective potential in this patient population.
  • “Our phase 2 CALLIPER trial is designed to corroborate the neuroprotective potential of vidofludimus calcium in a progressive patient population.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in August

Retrieved on: 
Dienstag, August 1, 2023
Biotechnology, ISNI, Multiple sclerosis, Patient, NURR1, Congress, Pharmacology, International Congress of Americanists, Conference, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, August 1, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:

Key Points: 
  • NEW YORK, August 1, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:
    August 8-9: 2023 Wedbush PacGrow Healthcare Conference.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Vidofludimus Calcium, an Orally Available DHODH Inhibitor in Phase 3 Clinical Trials for Multiple Sclerosis, Potently Activates NURR1

Immunic to Participate in Investor and Scientific Conferences in August

Retrieved on: 
Dienstag, August 1, 2023
ISNI, Multiple sclerosis, Patient, NURR1, Congress, Pharmacology, International Congress of Americanists, Conference, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:

Key Points: 
  • NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:
    August 8-9: 2023 Wedbush PacGrow Healthcare Conference.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Vidofludimus Calcium, an Orally Available DHODH Inhibitor in Phase 3 Clinical Trials for Multiple Sclerosis, Potently Activates NURR1

Immunic to Participate in Scientific and Investor Conferences in July

Retrieved on: 
Donnerstag, Juni 29, 2023
Mayo Clinic, Clinic, Beth Israel Deaconess Medical Center, Biotechnology, Clinical trial, Regeneration, Virology, Harvard Medical School, Hepatology, Division, Internal medicine, Human, Webcast, Poster, Pharmacology, Coeliac disease, Treatment, Pharmaceutical industry, Vaccine, Dentistry, Gastroenterology, Short course immune induction therapy, Medicine

The poster presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • Immunic's collaboration partner will present a poster and participate in a satellite workshop at this conference in Missoula, Montana.
  • An archived replay of the webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

EQS-News: Immunic to Participate in Scientific and Investor Conferences in June

Retrieved on: 
Donnerstag, Juni 1, 2023
Aurora, Cleveland Clinic, Biotechnology, Multiple sclerosis, CMSC, MD, Neurological Institute of New York, Research, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:

Key Points: 
  • NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:
    May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunic’s management and business development teams will attend this conference in Boston and participate in partnering activities.
  • To schedule a meeting, please use the BIO International Convention partnering portal .

Immunic to Participate in Scientific and Investor Conferences in June

Retrieved on: 
Dienstag, Mai 30, 2023
Aurora, Cleveland Clinic, Biotechnology, Multiple sclerosis, CMSC, MD, Neurological Institute of New York, Research, Vaccine, Short course immune induction therapy

NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:

Key Points: 
  • NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:
    May 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunic's management and business development teams will attend this conference in Boston and participate in partnering activities.
  • To schedule a meeting, please use the BIO International Convention partnering portal .

EQS-News: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Retrieved on: 
Mittwoch, Mai 17, 2023
Neuroprotection, Sclerosis, Medicinal chemistry, GFAP, Glial fibrillary acidic protein, Ludwig Maximilian University of Munich, AFL, Biotechnology, Medication, DHODH, Journal of Medicinal Chemistry, Patent, Patient, Calcium, Frankincense, Pharmaceutical industry, Vaccine, Multiple sclerosis, Short course immune induction therapy

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Key Points: 
  • Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
    The issuer is solely responsible for the content of this announcement.
  • Activation of Nurr1 could be responsible for the drug’s postulated neuroprotective effects and may contribute to the previously reported reduction of confirmed disability worsening events in multiple sclerosis patients.
  • Specifically, preclinical data shows potent Nurr1 activation by vidofludimus calcium at low concentrations in several test systems.
  • In preclinical testing, we have discovered strong Nurr1 agonism by vidofludimus calcium,” stated Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic.

EQS-News: Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Retrieved on: 
Samstag, Mai 6, 2023
Molecule, Paneth cell, Gastrointestinal disease, Histology, Diarrhea, Gastrointestinal tract, Epithelium, Biotechnology, Clinical trial, Irritable bowel syndrome, Biomarker, Ulcerative colitis, DDW, Regeneration, Enterocyte, Patient, Action, Poster, B cell, Coeliac disease, DSS, Vaccine, Pharmaceutical industry, Paneth, Short course immune induction therapy, SIRT6

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Key Points: 
  • Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
    The issuer is solely responsible for the content of this announcement.
  • The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.
  • In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining.
  • Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Retrieved on: 
Samstag, Mai 6, 2023
Molecule, Paneth cell, Histology, Diarrhea, Gastrointestinal tract, Epithelium, Clinical trial, Irritable bowel syndrome, Biomarker, Ulcerative colitis, DDW, Crohn's disease, Regeneration, Enterocyte, Patient, Poster, B cell, Coeliac disease, Phenotype, DSS, Pharmaceutical industry, Vaccine, Paneth, Short course immune induction therapy, SIRT6

NEW YORK, May 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of clinical and preclinical data for IMU-856. Included in this presentation are new data on IMU-856's mode of action as a potent modulator of SIRT6 (Sirtuin 6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.

Key Points: 
  • The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.
  • In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining.
  • Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • That said, we are preparing for a phase 2b clinical trial of IMU-856 in celiac disease patients, while also considering other indications."